Drugs / EPs® 7630
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT06353477 Comparator | Jun 2019 → Jun 2022 | hand, foot and mouth disease | Eskisehir Osmangazi University | Completed | No outcome recorded |
| Phase 3 | NCT02174653 Comparator | Mar 2014 → Jul 2015 | common cold | Dr. Willmar Schwabe GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPs 7630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06353477 ↗ |
| Known as | Umca | “EPs® 7630 by oral route [Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children >12 years of age)] for 7 days” NCT06353477 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “herbal drug EPs® 7630” NCT06353477 ↗ |
| Route | Oral | “Orally intake three times a day (in the morning, midday and evening)” NCT02174653 ↗ |